CN112739696A - 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用 - Google Patents

作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用 Download PDF

Info

Publication number
CN112739696A
CN112739696A CN201980041955.2A CN201980041955A CN112739696A CN 112739696 A CN112739696 A CN 112739696A CN 201980041955 A CN201980041955 A CN 201980041955A CN 112739696 A CN112739696 A CN 112739696A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
reaction
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980041955.2A
Other languages
English (en)
Other versions
CN112739696B (zh
Inventor
毛魏魏
钱文远
郑学建
胡国平
韦昌青
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of CN112739696A publication Critical patent/CN112739696A/zh
Application granted granted Critical
Publication of CN112739696B publication Critical patent/CN112739696B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00

Abstract

本发明公开了作为JAK抑制剂的[1,2,4]三唑并[1,5‑a]吡啶类化合物，以及在制备治疗JAK1或/和TYK2相关疾病的药物中的应用。具体涉及式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201980041955.2A 2018-08-23 2019-08-23 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用 Active CN112739696B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018109682076 2018-08-23
CN201810968207 2018-08-23
PCT/CN2019/102209 WO2020038457A1 (zh) 2018-08-23 2019-08-23 作为JAK抑制剂的[1，2，4]三唑并[1，5-a]吡啶类化合物及其应用

Publications (2)

Publication Number Publication Date
CN112739696A true CN112739696A (zh) 2021-04-30
CN112739696B CN112739696B (zh) 2022-08-02

Family

ID=69592871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980041955.2A Active CN112739696B (zh) 2018-08-23 2019-08-23 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用

Country Status (9)

Country Link
US (1) US11919896B2 (zh)
EP (1) EP3842431B1 (zh)
JP (1) JP7140920B2 (zh)
KR (1) KR102603729B1 (zh)
CN (1) CN112739696B (zh)
AU (1) AU2019326647B2 (zh)
CA (1) CA3106490C (zh)
RS (1) RS65243B1 (zh)
WO (1) WO2020038457A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066425A (zh) * 2020-02-13 2022-09-16 珠海联邦制药股份有限公司 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
US20240033255A1 (en) 2021-01-29 2024-02-01 Zhuhai United Laboratories Co., Ltd. Oral preparation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor, and application thereof
AU2022330231A1 (en) 2021-08-19 2024-04-04 Zhuhai United Laboratories Co., Ltd. Local topical formulation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor and application thereof
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
WO2018019223A1 (zh) * 2016-07-26 2018-02-01 张文燕 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
CN108341814A (zh) * 2017-01-23 2018-07-31 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220688A1 (en) 2005-07-27 2009-09-03 Buddy Tools, Llc Drywall tape and joint compound dispenser
WO2010010187A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2939286A1 (en) * 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
CA3072346A1 (en) * 2017-08-14 2019-02-21 Camp4 Therapeutics Corporation Methods of treating liver diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
WO2018019223A1 (zh) * 2016-07-26 2018-02-01 张文燕 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
CN108341814A (zh) * 2017-01-23 2018-07-31 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066425A (zh) * 2020-02-13 2022-09-16 珠海联邦制药股份有限公司 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
CN115066425B (zh) * 2020-02-13 2023-06-23 珠海联邦制药股份有限公司 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用

Also Published As

Publication number Publication date
EP3842431A4 (en) 2022-06-01
EP3842431C0 (en) 2023-12-27
US11919896B2 (en) 2024-03-05
AU2019326647A1 (en) 2021-02-18
EP3842431B1 (en) 2023-12-27
US20210155621A1 (en) 2021-05-27
JP7140920B2 (ja) 2022-09-21
CA3106490C (en) 2023-03-07
CN112739696B (zh) 2022-08-02
AU2019326647B2 (en) 2022-02-10
JP2021534259A (ja) 2021-12-09
CA3106490A1 (en) 2020-02-27
EP3842431A1 (en) 2021-06-30
KR102603729B1 (ko) 2023-11-17
RS65243B1 (sr) 2024-03-29
KR20210049858A (ko) 2021-05-06
WO2020038457A1 (zh) 2020-02-27

Similar Documents

Publication Publication Date Title
CN112739696B (zh) 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
US20230322732A1 (en) RIP1 Inhibitory Compounds and Methods for Making and Using the Same
EP2590981B1 (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
BG62002B1 (bg) (-)-[[4-(1,4,5,6-тетрахидро-4-метил-6-оксо-3-пиридазинил)фенил]хидразоно]пропандинитрил
AU2020378407B2 (en) Heterocyclic RIP1 inhibitory compounds
JP2022547617A (ja) Ｉｌ－１７ａモジュレーターおよびその使用
CN115413279A (zh) P2x3调节剂
WO2021159372A1 (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
EP4149927A1 (en) Enpp1 modulators and uses thereof
CN111566091A (zh) 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基衍生物
CN111479810B (zh) Jak抑制剂及其应用
WO2020120606A1 (en) New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
WO2020021015A1 (en) New imidazopyridine derivatives for treating pain and pain related conditions
JPH0211592A (ja) 光学活性なジヒドロピリジンホスホン酸エステル

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant